Non ci sono recensioni
ix
Contents
Part I: Genetics and the Epidemiology of Leukemia in Children
1 Epidemiology of Acute Childhood Leukemia . . . . . . . . . . . . . . . . . . . . . 3
Julie A. Ross, Kimberly J. Johnson,
Logan G. Spector, and John H. Kersey
Part II: Biology of Pediatric Leukemia
2 The Biology of Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . 29
William L. Carroll, Mignon Loh,
Andrea Biondi, and Cheryl Willman
3 Biology of Acute Myeloid Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Robert J. Arceci and Soheil Meshinchi
Part III: Treatment Considerations in Childhood Leukemia
4 Classification and Treatment of Acute Lymphoblastic Leukemia . . . . 79
Stephen P. Hunger, Valentino Conter, Elizabeth A. Raetz,
Maria Grazia Valsecchi, and Guenter Henze
5 Treatment of Acute Myeloid Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . 121
Brenda Gibson, John Perentesis, Todd A. Alonzo, and
Gertjan J.L. Kaspers
Part IV: The Impact of Pharmacogenetics and Pharmacogenomics
on Childhood Leukemia
6 Pharmacogenetic and Pharmacogenomic Considerations
in the Biology and Treatment of Childhood Leukemia . . . . . . . . . . . . . 163
Jun J. Yang, Parinda A. Mehta, Mary V. Relling, and Stella M. Davies
Part V: The Potential Role of Biologically Targeted Therapy
for Childhood Leukemia
7 Promising Targeted Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
Patrick Brown, Gregory H. Reaman, Nita L. Seibel, and Pamela Kearns
x Contents
8 Strategies for New Agent Development and Clinical
Trial Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
Malcolm Smith, Meenakshi Devidas, Keith Wheatley,
Richard B. Lock, and Sally Hunsberger
Part VI: Late Effects of Leukemia and Its Therapy
9 Late Sequelae in Children with Acute
Lymphoblastic Leukemia: Impact on Long-Term
Survival and Quality of Life . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245
Joseph P. Neglia, Maura O’Leary, and Smita Bhatia
10 Acute Toxicities, Late Sequelae, and Quality of Survivorship
in Children with Acute Myeloid Leukemia:
The Impact of Allogeneic Stem Cell Transplant . . . . . . . . . . . . . . . . . . 265
Julianne Byrne, John Horan, and H. Stacy Nicholson
part VII: Psychosocial Implications of Acute Leukemia Diagnosis
and Treatment for Children and Families
11 Appreciation and the Interdisciplinary Management
of the Psychosocial Impact of Leukemia on Children
and Their Families . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285
Anne L. Angiolillo, Momcilo Jankovic, Riccardo Haupt,
Kathleen Ruccione, E. Anne Lown, and Robert B. Noll
Part VIII: Global Strategies to Improve Leukemia
Care and Outcome for Children
12 Improved Outcome for Children with Acute Leukemia:
How to Address Global Disparities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
Yaddanapudi Ravindranath, Hans Peter Wagner,
Giuseppe Masera, Fulgencio Baez, Anjo.J.P. Veerman,
Jacqueline Cloos, Raul Ribeiro, and Gregory H. Reaman
Part IX: Perspectives and Future Direction
13 Future Challenges and Opportunities to Improve
Outcomes for Children with Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . 325
Gregory H. Reaman and Franklin O. Smith
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331
Sei sicuro di voler eseguire questa azione?